Technology Bundle ID: TAB-2638

Isolated Lyssavirus Nucleic Acid and Protein Sequences

Request More Info
Primary Inventors: 
Ivan Kuzmin (CDC)
Co-Inventors: 
Charles Rupprecht (CDC), Wanda Markotter (University of Pretoria)
Therapeutic Area: 
Infectious Disease
Development Status: 
  • Early-stage
  • In vitro data available
Institute or Center: 
CDC

A novel strain in the rabies family of viruses, the Shimoni bat virus (SHIBV), has been discovered. Phylogenic and antigenic patterns identify SHIBV as a new species of Lyssavirus. Phylogenic reconstructions of SHIBV and monoclonal antibody typing were used to demonstrate a distinct genetic antigenic pattern. This unique genetic information may be used to create antigens or vaccines against SHIBV and provides opportunity for the development of new diagnostics, therapeutics, and prophylactic therapies for viral infection.

Applications:
  • Vaccines, therapies or diagnostics for Shimoni bat virus
  • Rabies epidemiology and surveillance
  • Lyssavirus/rabies research tool
Advantages:
  • Protects against phylogroup II lyssaviruses, unlike current commercially available rabies vaccines
  • Isolated biomaterials provide novel lyssavirus research tools

Patents

PCT Application PCT/US11/021309
Filed on 2011-01-14
US Application 61/294,988
Filed on 2010-01-14

Publications

Kuzmin IV, et al.
PMID 20138934
Kuzmin IV, et al.
PMID 21867415

Updated

Sep 17, 2013

Data Source: 
tts